Lixte Biotechnology Warrants
LIXTW
LIXTW was delisted on the 26th of November, 2025.
3 hedge funds and large institutions have $339K invested in Lixte Biotechnology Warrants in 2020 Q4 according to their latest regulatory filings, with 3 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
0.56% more ownership
Funds ownership: 0% → 0.56% (+0.56%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$306K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$20.9K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SM
1
Sabby Management
Miami Beach,
Florida
| $306K | +$306K | +339,542 | New |
|
|
2
UBS Group
Zurich,
Switzerland
| $21K | +$20.9K | +23,240 | New |
|
|
WAM
3
Warberg Asset Management
Winnetka,
Illinois
| $12K | +$11.7K | +13,001 | New |
|
LIXTW Hedge Fund Activity: Q4 2020 in Review
3 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Lixte Biotechnology Warrants (LIXTW) for Q4 2020, worth a combined $339K.
Buyers outnumbered sellers: 3 funds opened new LIXTW positions and 0 closed out — a net gain of 3 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Sabby Management, opening a new position worth an estimated $306K.
- 3 institutional investors held Lixte Biotechnology Warrants (LIXTW) as of Q4 2020, up from 0 in Q3 2020.
- Funds reported $339K of Lixte Biotechnology Warrants stock for Q4 2020.
- 3 funds opened new Lixte Biotechnology Warrants positions in Q4 2020 and 0 closed out, a net change of +3 holders.
- The largest Lixte Biotechnology Warrants buyer in Q4 2020 was Sabby Management, an estimated $306K added.
Based on aggregated 13F filings for Q4 2020.